galantamine has been researched along with Disease Models, Animal in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.32) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (27.63) | 29.6817 |
| 2010's | 46 (60.53) | 24.3611 |
| 2020's | 8 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, YH; Lee, YS; Nam, SO; Park, DH; Ryu, JH | 1 |
| Darekar, MN; Gurjar, AS; Ooi, L; Yeong, KY | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Alexandrova, A; Georgieva, A; Kalfin, R; Lazarova, M; Petkova-Kirova, P; Stefanova, M; Tancheva, L; Tsekova, D; Tsvetanova, E; Uzunova, D; Vezenkov, L | 1 |
| Allam, M; El-Ganainy, SO; Elbahnasi, AI; Ghazy, AA; Gowayed, MA; Mansour, AM; Soliman, OA | 1 |
| Al-Abed, Y; Chae, JJ; Diamond, B; Kastner, DL; Mughrabi, IT; Ochani, M; Ozen, S; Pavlov, VA; Sherry, B; Tanovic, M; Wang, P | 1 |
| Emoto, MC; Fujii, HG; Hisahara, S; Iwahara, N; Kawamata, J; Manabe, T; Matsumura, A; Matsushita, T; Saito, T; Sato-Akaba, H; Shimohama, S; Suzuki, H; Suzuki, S; Yokokawa, K | 1 |
| Gzielo, K; Krawczyk, M; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Basar, MK; Baykal, AT; Coskun, J; Gurel, B; Kiris, I; Mroczek, T; Sahin, B | 1 |
| Abdallah, DM; El Achy, S; El-Abhar, HS; El-Emam, MA; Gowayed, MA | 1 |
| Emad Aboulhoda, B; Gamal, M; Magdy, S; Mohammed, HS; Rashed, L; Samir, NF; Sharawy, N | 1 |
| Arias, HR; Manetti, D; Romanelli, MN; Wadenberg, MG | 1 |
| Koola, MM | 1 |
| Abe, K; Hishikawa, N; Huang, Y; Li, X; Liu, X; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Shang, J; Shi, X; Takemoto, M; Tian, F; Yamashita, T; Zhai, Y | 1 |
| Mishra, DN; Singh, SK | 1 |
| Mathis, KW; Pham, GS; Wang, LA | 1 |
| Almasieh, M; Casanova, C; Di Polo, A; Kelly, ME; MacIntyre, JN; Pouliot, M; Vaucher, E | 1 |
| Baqi, Y; Collins-Praino, LE; Kovner, R; Ledgard, F; Müller, CE; Paul, NE; Podurgiel, SJ; Salamone, JD; Senatus, PB | 1 |
| Di, R; Lawton, MA; Long, C; Wang, H; Wang, Y; Wu, WH; Xin, L; Yamujala, R | 1 |
| Ghia, JE; Ji, H; Labis, B; Pavlov, VA; Rabbi, MF; Tracey, KJ | 1 |
| Amatya, C; Dalhoff, Z; DeSaer, CJ; Eggerichs, MR; Ramakrishnan, L | 1 |
| Bhattacharya, S; Haertel, C; Maelicke, A; Montag, D | 1 |
| Callaerts-Vegh, Z; D'Hooge, R; De Maeyer, JH; Lo, AC; Schuurkes, JA; Vermaercke, B | 1 |
| Adeghate, E; Devavaram Jackson, D; Jebasingh, D; Starling Emerald, B; Venkataraman, S | 1 |
| Bogo, MR; Capiotti, KM; Da Silva, RS; De Moraes, DA; Kist, LW; Menezes, FP | 1 |
| Du, W; Li, M; Shao, F; Shao, S; Wang, W | 1 |
| Bhattacharya, S; Maelicke, A; Montag, D | 1 |
| Babri, S; Mahmoudi, J; Sadigh-Eteghad, S; Shanehbandi, D; Talebi, M | 1 |
| Ali, MA; Attia, AS; El-Abhar, HS; Kamel, MA | 1 |
| Chen, X; Cheng, X; Wu, Z; Zhang, Y; Zhao, L | 1 |
| Babri, S; Mahmoudi, J; Sadigh-Eteghad, S; Talebi, M | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Shang, J; Yamashita, T; Zhai, Y | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Sun, Z; Yamashita, T; Zhai, Y | 1 |
| Matsuda, T | 1 |
| Darwish, AS; Kamal, SM; Wahba, SM | 1 |
| Abe, K; Feng, T; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Shang, J; Sun, Z; Yamashita, T; Zhai, Y | 1 |
| Kos, T; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Caporaso, R; Cavalli, A; Keller, E; Maurice, T; Meunier, J; Minarini, A; Reggiani, AM; Rosini, M; Simoni, E | 1 |
| Bondi, CO; Cheng, JP; de la Tremblaye, PB; Kline, AE; Lajud, N; Radabaugh, HL | 1 |
| Wightman, EL | 1 |
| Chuang, TT; Gil-Bea, FJ; Marcos, B; Ramirez, MJ | 1 |
| Kishimoto, K; Kitamura, Y; Minamino, H; Shibaike, T; Shimohama, S; Takata, K; Takeuchi, H; Taniguchi, T; Tsushima, J; Yanagida, T; Yasui, H | 1 |
| Chu, K; Im, WS; Kim, M; Lee, ST; Park, JE | 1 |
| Benetti, F; Bonini, JS; Cammarota, M; Izquierdo, I; Mello, PB; Monteiro, S | 1 |
| Amenta, F; Di Tullio, MA; Tayebati, SK | 1 |
| Kano, M; Kurinami, H; Morishita, R; Niisato, K; Rakugi, H; Sato, N; Shinohara, M; Takeda, S; Takeuchi, D | 1 |
| Tang, XC; Wang, J; Zhang, HY | 1 |
| Clark, MG; Finneran, K; Hilmas, CJ; Poole, MJ; Williams, PT | 1 |
| Hoeffle-Maas, A; Jordis, U; Koepke, AK; Ludwig, J; Maelicke, A; Maus, A; Samochocki, M | 1 |
| Federley, M; Fjällström, AK; Persson, P; Stenqvist, P; Wadenberg, ML | 1 |
| Ago, Y | 1 |
| Fujikawa, Y; Kagitani, S; Kitamura, R; Kitamura, Y; Maelicke, A; Saeki, M; Shimohama, S; Takata, K; Taniguchi, T; Terada, M; Tomimoto, H | 1 |
| Ilavazhagan, G; Maiti, P; Muthuraju, S; Pati, S; Prasad, D; Sharma, AK; Singh, SB; Solanki, P | 1 |
| Aw, CC; Browne, ER; Chan, EC; Chang, KL; Goh, CW; Mal, M; New, LS | 1 |
| Kumar, A; Pahwa, D; Prakash, A | 1 |
| Abbas, SF; Baqi, Y; Chrobak, JJ; Collins, LE; Galtieri, DJ; Leser, CE; Müller, CE; Paul, NE; Podurgiel, SJ; Salamone, JD | 1 |
| Ago, Y; Fukada, A; Kita, Y; Koda, K; Matsuda, T; Ota, Y; Takuma, K | 1 |
| Albuquerque, EX; Kulkarni, GS; Mamczarz, J; Pereira, EF | 1 |
| Alexander, KS; Bruno, JP; Schwarcz, R; Wu, HQ | 1 |
| Blatner, M; Busquet, N; de Souza, FM; Maclean, KN; Restrepo, D | 1 |
| Ago, Y; Matsuda, T; Takuma, K | 1 |
| Bertorelli, R; Busquet, P; Capurro, V; Cavalli, A; Piomelli, D; Reggiani, A | 1 |
| Capsoni, S; Cattaneo, A; Giannotta, S | 1 |
| Bellack, AS; Billingslea, EN; Deutsch, SI; Mastropaolo, J; Rosse, RB | 1 |
| Geerts, H | 1 |
| Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D | 1 |
| De Deyn, PP; Van Dam, D | 1 |
| Dimitrova, DS; Getova-Spassova, DP | 1 |
| Furukawa, H; Nabeshima, T; Nitta, A; Noda, Y; Wang, D; Zhou, Y | 1 |
| Chen, Y; Guo, L; Ji, X; Li, C; Lu, Y | 1 |
| Deutsch, SI; Gaskins, BL; Long, KD; Mastropaolo, J; Rosse, RB; Schooler, NR; Schwartz, BL | 1 |
| Amatniek, J; Coyle, JT; Geerts, H; Sorra, K | 1 |
| Agelan, A; Del Valle, L; Woodruff-Pak, DS | 1 |
| Santos, IS; Woodruff-Pak, DS | 1 |
| Goa, KL; Scott, LJ | 1 |
| Dimitrov, P; Michailov, M; Zlateva, M; Zografski, B | 1 |
8 review(s) available for galantamine and Disease Models, Animal
| Article | Year |
|---|---|
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; Drug Discovery; Environment; Female; Galantamine; Indans; Male; Mental Disorders; Mice; Molecular Targeted Therapy; Motivation; Piperidines; Psychopharmacology; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1D; Receptors, Dopamine D2; Research; Rivastigmine | 2016 |
Potential benefits of phytochemicals against Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Ginkgo biloba; Humans; Melissa; Panax; Phytochemicals; Plant Extracts; Resveratrol; Rivastigmine; Salvia officinalis; Stilbenes; Terpenes | 2017 |
Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
Topics: Acetylcholine; Alkaloids; Animals; Anti-Inflammatory Agents; Cholinergic Agents; Cholinesterase Inhibitors; Dementia, Vascular; Disease Models, Animal; Donepezil; Galantamine; Humans; Indans; Inflammation; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, Cholinergic; Rivastigmine; Sesquiterpenes; Signal Transduction | 2009 |
[Beneficial effect of galantamine on sensory information-processing deficits].
Topics: Acetylcholine; Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Humans; Mice; Prefrontal Cortex; Receptors, Muscarinic; Reflex, Startle; Sensation Disorders | 2010 |
[Pharmacological profiles of galantamine: the involvement of muscarinic receptor].
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Humans; Mice; Receptors, Muscarinic | 2012 |
Indicators of neuroprotection with galantamine.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Galantamine; Glutamic Acid; Humans; In Vitro Techniques; Indicators and Reagents; Models, Biological; Neuroprotective Agents; Treatment Outcome | 2005 |
Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
Topics: Allosteric Regulation; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Humans; Nootropic Agents; Receptors, Nicotinic | 2007 |
Galantamine: a review of its use in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Disease Models, Animal; Galantamine; Humans | 2000 |
68 other study(ies) available for galantamine and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Coumarins; Disease Models, Animal; Enzyme Activation; Male; Memory; Memory Disorders; Mice; Mice, Inbred ICR; Protein Binding; Pyrrolidines; Scopoletin; Structure-Activity Relationship | 2014 |
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophorus; Female; Horses; Imidazoles; Male; Maze Learning; Memory Disorders; Mice; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice.
Topics: Alzheimer Disease; Animals; Antioxidants; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Male; Memory, Long-Term; Memory, Short-Term; Mice; Scopolamine | 2021 |
Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cognitive Dysfunction; Disease Models, Animal; Female; Galantamine; Glycogen Synthase Kinase 3 beta; MAP Kinase Signaling System; Oxytocin; Rats; tau Proteins | 2022 |
Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever.
Topics: Acetylcholinesterase; Animals; Disease Models, Animal; Familial Mediterranean Fever; Galantamine; Inflammation; Mice | 2022 |
Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Galantamine; Humans; Inflammation; Mice; Microglia; Oxidative Stress; Protein Aggregation, Pathological; Reactive Oxygen Species; Ribosomal Proteins; RNA-Binding Proteins | 2019 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Synergism; Excitatory Amino Acid Antagonists; Galantamine; Isoxazoles; Memantine; Nootropic Agents; Phenylurea Compounds; Rats; Recognition, Psychology; Scopolamine | 2020 |
Evaluation of the Therapeutic Effect of Lycoramine on Alzheimer's Disease in Mouse Model.
Topics: Alzheimer Disease; Amaryllidaceae Alkaloids; Amyloid beta-Peptides; Animals; Disease Models, Animal; Galantamine; Mice; Mice, Transgenic | 2021 |
Neuroprotective role of galantamine with/without physical exercise in experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Apoptosis; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Galantamine; Male; Multiple Sclerosis; Neurons; Neuroprotection; Neuroprotective Agents; Physical Conditioning, Animal; Physical Exertion; Rats; Rats, Sprague-Dawley | 2021 |
IκB kinase inhibition remodeled connexins, pannexin-1, and excitatory amino-acid transporters expressions to promote neuroprotection of galantamine and morphine.
Topics: Animals; Anti-Inflammatory Agents; Brain; Connexins; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Galantamine; Glutamic Acid; I-kappa B Kinase; Lipopolysaccharides; Male; Morphine; Nerve Tissue Proteins; Neurodegenerative Diseases; Neuroglia; Neurons; Neuroprotection; Neuroprotective Agents; Nitriles; Rats, Sprague-Dawley; Signal Transduction; Sulfones | 2021 |
Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat.
Topics: Acrylamides; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Cognition Disorders; Discrimination, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Furans; Galantamine; Male; Phencyclidine; Rats; Rats, Wistar; Statistics, Nonparametric; Time Factors | 2017 |
Galantamine and memantine combination for cognition: Enough or more than enough to translate from murines and macaques to men with schizophrenia?
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Galantamine; Humans; Memantine; Neurotransmitter Agents; Nootropic Agents | 2019 |
Acceleration of NLRP3 inflammasome by chronic cerebral hypoperfusion in Alzheimer's disease model mouse.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain Ischemia; Caspase 1; Cerebral Cortex; Cerebrovascular Circulation; Collagen; Disease Models, Animal; Galantamine; Inflammasomes; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein | 2019 |
Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Topics: Acetylcholinesterase; Adhesiveness; Administration, Intranasal; Administration, Oral; Alzheimer Disease; Animals; Behavior, Animal; Biological Availability; Blood-Brain Barrier; Chitosan; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Galantamine; Humans; Male; Maze Learning; Mice; Nanoparticles; Nasal Mucosa; Nootropic Agents; Piracetam; Scopolamine; Treatment Outcome | 2019 |
Pharmacological potentiation of the efferent vagus nerve attenuates blood pressure and renal injury in a murine model of systemic lupus erythematosus.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Hypertension; Kidney; Mice, Transgenic; Neurons, Efferent; Vagus Nerve | 2018 |
Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma.
Topics: Acetylcholinesterase; Animals; Autoradiography; Cell Count; Cell Survival; Cholinesterase Inhibitors; Disease Models, Animal; Fluorescent Antibody Technique, Indirect; Galantamine; Injections, Intraperitoneal; Intraocular Pressure; Male; Ocular Hypertension; Rats; Rats, Inbred BN; Receptors, Muscarinic; Regional Blood Flow; Retinal Ganglion Cells; Retinal Vessels; Vasodilation | 2013 |
Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.
Topics: Adenosine A2 Receptor Antagonists; Animals; Deep Brain Stimulation; Disease Models, Animal; Dopamine Antagonists; Galantamine; Jaw; Male; Movement; Parkinson Disease, Secondary; Pilocarpine; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus; Tremor; Xanthines | 2013 |
Acetylcholineestarase-inhibiting alkaloids from Lycoris radiata delay paralysis of amyloid beta-expressing transgenic C. elegans CL4176.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Gene Expression; Humans; Longevity; Lycoris; Oxidative Stress; Paralysis; Peptide Fragments; Phenanthridines | 2013 |
Central cholinergic activation of a vagus nerve-to-spleen circuit alleviates experimental colitis.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cholinesterase Inhibitors; Colitis; Cytokines; Disease Models, Animal; Galantamine; Ligands; Male; Mice; Receptors, Muscarinic; Severity of Illness Index; Signal Transduction; Spleen; Vagus Nerve | 2014 |
Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.
Topics: Animals; Cholinesterase Inhibitors; Conditioning, Classical; Disease Models, Animal; Dose-Response Relationship, Drug; Galantamine; Hyperkinesis; Locomotion; Memory; Muscarinic Antagonists; Planarians; Scopolamine; Stereotypic Movement Disorder; Time Factors | 2014 |
Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Female; Galantamine; Male; Maze Learning; Mice; Neurons; Plaque, Amyloid; Sex Factors | 2014 |
SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl/6 mice.
Topics: Animals; Anxiety; Avoidance Learning; Benzofurans; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Galantamine; Male; Maze Learning; Memory Disorders; Mice, Inbred C57BL; Nootropic Agents; Piperidines; Random Allocation; Receptors, Serotonin, 5-HT4; Scopolamine; Serotonin 5-HT4 Receptor Agonists | 2014 |
The protective effects of Cyperus rotundus on behavior and cognitive function in a rat model of hypoxia injury.
Topics: Animals; Behavior, Animal; Cognition Disorders; Cyperus; Disease Models, Animal; Dose-Response Relationship, Drug; Galantamine; Hypoxia; Male; Medicine, Ayurvedic; Motor Activity; Plant Extracts; Pyrithioxin; Rats; Rats, Wistar; Sodium Nitrite | 2014 |
Hyperglycemia induces memory impairment linked to increased acetylcholinesterase activity in zebrafish (Danio rerio).
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Avoidance Learning; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Escape Reaction; Female; Galantamine; Gene Expression Regulation; Glucose; Glucose Transporter Type 3; Hyperglycemia; Male; Memory Disorders; Motor Activity; Receptor, Insulin; Zebrafish | 2014 |
Galanthamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment.
Topics: Age Factors; Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Galantamine; Male; Prepulse Inhibition; Rats; Rats, Wistar; Social Isolation; Spatial Learning | 2014 |
Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinesterase Inhibitors; Conditioning, Psychological; Disease Models, Animal; Fear; Galantamine; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Muscle Strength; Mutation; Plaque, Amyloid; Presenilin-1; Prodrugs | 2015 |
Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Galantamine; Gene Expression Regulation; Male; Maze Learning; Mice; Mice, Inbred BALB C; Nicotinic Agonists; Nicotinic Antagonists; Peptide Fragments; Psychomotor Performance; Quinuclidines; RNA, Messenger; Time Factors | 2015 |
Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug.
Topics: Adipokines; Animals; Apoptosis; Biomarkers; Blood Glucose; Body Weight; Brain; Caspase 3; Cholinesterase Inhibitors; Cytochromes c; Diabetes Mellitus, Experimental; Disease Models, Animal; Galantamine; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Inflammation Mediators; Insulin; Lipid Metabolism; Lipids; Liver; Muscle, Skeletal; Rats; Signal Transduction; Wnt Signaling Pathway | 2015 |
Galantamine attenuates amyloid-β deposition and astrocyte activation in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Disease Models, Animal; Galantamine; Hippocampus; Interleukin-6; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurogenesis; Tumor Necrosis Factor-alpha | 2015 |
Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Laser-Doppler Flowmetry; Male; Memory Disorders; Mice, Inbred BALB C; Neuropsychological Tests; Neurovascular Coupling; Peptide Fragments; Quinuclidines; Recognition, Psychology; Reproducibility of Results; Time Factors; Treatment Outcome | 2015 |
Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit, Cerebrovascular Remodeling, and Neurovascular Trophic Coupling in Alzheimer's Disease Model Mouse.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cerebrovascular Disorders; Disease Models, Animal; Disease Progression; Galantamine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Neuroprotective Agents; Neurovascular Coupling; Nootropic Agents; Receptors, Nicotinic | 2016 |
Disruption of White Matter Integrity by Chronic Cerebral Hypoperfusion in Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Ankyrins; Brain Ischemia; Cell Adhesion Molecules; Corpus Callosum; Disease Models, Animal; Galantamine; Male; Mice; Mice, Inbred C57BL; Myelin-Associated Glycoprotein; Nerve Growth Factors; Nootropic Agents; White Matter | 2016 |
Ceria-containing uncoated and coated hydroxyapatite-based galantamine nanocomposites for formidable treatment of Alzheimer's disease in ovariectomized albino-rat model.
Topics: Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Cortex; Cerium; Chitosan; Chlorides; Disease Models, Animal; Drug Carriers; Durapatite; Dynamic Light Scattering; Female; Galantamine; Hippocampus; Nanocomposites; Ovariectomy; Rats; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |
Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Carotid Stenosis; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Gene Expression Regulation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Models, Cardiovascular; Plaque, Amyloid; Postural Balance; Psychomotor Performance; Receptors, Nicotinic; White Matter | 2016 |
The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Galantamine; Male; Memantine; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic | 2016 |
In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Galantamine; Memantine; Mice; Mice, Transgenic; Peptide Fragments | 2016 |
Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined.
Topics: Animals; Behavior, Animal; Brain Injuries, Traumatic; Cholinesterase Inhibitors; Cognitive Dysfunction; Combined Modality Therapy; Disease Models, Animal; Environment; Galantamine; Male; Maze Learning; Neurological Rehabilitation; Psychomotor Performance; Rats; Rats, Sprague-Dawley | 2017 |
Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Drug Administration Schedule; Drug Therapy, Combination; Galantamine; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Receptors, Serotonin; Scopolamine; Serotonin Antagonists; Sulfonamides; Thiophenes; Yawning | 2008 |
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electron Spin Resonance Spectroscopy; Functional Laterality; Galantamine; Gene Expression Regulation; Male; Mecamylamine; Methamphetamine; Motor Activity; Neuroprotective Agents; Nicotine; Nicotinic Antagonists; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Nicotinic; RNA, Messenger; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2008 |
Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Galantamine; Huntington Disease; In Situ Nick-End Labeling; Male; Nerve Degeneration; Neurologic Examination; Nitro Compounds; Nootropic Agents; Propionates; Rats; Rats, Inbred Lew; Statistics, Nonparametric | 2008 |
Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine.
Topics: Acetylcholine; Acetylcholinesterase; Aging; Animals; Animals, Newborn; Brain; Disease Models, Animal; Donepezil; Female; Galantamine; Hippocampus; Indans; Learning Disabilities; Male; Maternal Deprivation; Memory Disorders; Neuropsychological Tests; Nootropic Agents; Piperidines; Rats; Rats, Wistar; Social Behavior | 2009 |
Vesicular acetylcholine transporter (VAChT) in the brain of spontaneously hypertensive rats (SHR): effect of treatment with an acetylcholinesterase inhibitor.
Topics: Animals; Biomarkers; Blood Pressure; Brain; Cerebellum; Cerebral Cortex; Cholinergic Fibers; Cholinesterase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Galantamine; Hippocampus; Hypertension; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Synaptic Transmission; Vesicular Acetylcholine Transport Proteins | 2008 |
Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Ventricles; Cognition Disorders; Disease Models, Animal; Galantamine; Hippocampus; Injections, Intraventricular; Long-Term Potentiation; Male; Memory; Memory Disorders; Mice; Mice, Inbred C57BL; Neurotoxins; Nootropic Agents; Peptide Fragments | 2009 |
Galantamine is a novel post-exposure therapeutic against lethal VX challenge.
Topics: Acetylcholinesterase; Animals; Antidotes; Atropine; Cholinesterase Inhibitors; Cholinesterase Reactivators; Diaphragm; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroencephalography; Erythrocytes; Galantamine; Guinea Pigs; Male; Muscle Fatigue; Muscle Tonus; Neurotoxicity Syndromes; Organothiophosphorus Compounds; Paralysis; Phrenic Nerve; Pralidoxime Compounds; Seizures; Time Factors | 2009 |
Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Brain Chemistry; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ferrets; Galantamine; Gastrointestinal Diseases; Humans; Mice; Scopolamine; Synaptic Transmission; Treatment Outcome | 2010 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Extrapyramidal Tracts; Galantamine; Haloperidol; Male; Mecamylamine; Motor Activity; Nicotinic Antagonists; Rats; Rats, Wistar; Receptors, Muscarinic; Risperidone; Schizophrenia; Scopolamine | 2011 |
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antibodies, Monoclonal; Binding Sites; Calcium Signaling; Calmodulin; Cells, Cultured; Choline; Cholinesterase Inhibitors; Disease Models, Animal; Female; Galantamine; Hippocampus; Humans; Male; Microglia; Nootropic Agents; Phagocytosis; Rats; Rats, Wistar; Receptors, Nicotinic | 2010 |
Possible role of cholinesterase inhibitors on memory consolidation following hypobaric hypoxia of rats.
Topics: Acetylcholine; Air Pressure; Altitude Sickness; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Hypoxia, Brain; Male; Maze Learning; Memory; Memory Disorders; Physostigmine; Rats; Rats, Sprague-Dawley; Time Factors; Treatment Outcome | 2011 |
Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.
Topics: Animals; Brain; Disease Models, Animal; Electron Transport Complex II; Galantamine; Gas Chromatography-Mass Spectrometry; Huntington Disease; Metabolome; Metabolomics; Mitochondria; Nitro Compounds; Nootropic Agents; Oxidative Stress; Propionates; Rats; Rats, Sprague-Dawley | 2011 |
Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Caffeic Acids; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Galantamine; Glutathione; Hippocampus; Kainic Acid; Lactones; Lipid Peroxidation; Maze Learning; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Nootropic Agents; Rats; Rats, Wistar; Succinate Dehydrogenase; Sulfones; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Galantamine; Jaw; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tremor | 2011 |
Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses.
Topics: Animals; Animals, Outbred Strains; Cell Line, Tumor; Cerebral Cortex; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Galantamine; Humans; Indans; Male; Mental Disorders; Mice; Muscarinic Antagonists; Piperidines; Receptors, Muscarinic | 2011 |
Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.
Topics: Animals; Behavior, Animal; Brain; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Extinction, Psychological; Female; Galantamine; Guinea Pigs; Lethal Dose 50; Maze Learning; Motor Activity; Neuroprotective Agents; Nootropic Agents; Reaction Time; Soman; Time Factors | 2011 |
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cognition; Cognition Disorders; Disease Models, Animal; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Nootropic Agents; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Nicotinic; Schizophrenia | 2012 |
Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Association Learning; Disease Models, Animal; Down Syndrome; Female; Galantamine; Humans; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Nootropic Agents; Odorants; Trisomy | 2011 |
Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.
Topics: Amnesia; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Galantamine; Male; Memantine; Mice; Mice, Inbred Strains; Recognition, Psychology; Scopolamine | 2012 |
Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antibodies; Choline O-Acetyltransferase; Cholinergic Agonists; Disease Models, Animal; Entorhinal Cortex; Galantamine; Humans; Mice; Mice, Knockout; Mice, Transgenic; Nerve Degeneration; Nerve Growth Factor; Phenotype; Phosphorylation; Recombinant Proteins; tau Proteins | 2002 |
Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Drug Antagonism; Galantamine; Image Processing, Computer-Assisted; Injections, Intraperitoneal; Male; Mice; Neuroprotective Agents; Parasympathomimetics; Schizophrenia | 2003 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Male; Memantine; Mice; Mice, Mutant Strains; Phenylcarbamates; Piperidines; Rivastigmine; Sensitivity and Specificity | 2005 |
Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Excitatory Amino Acid Antagonists; Galantamine; Humans; Maze Learning; Memantine; Mice; Mice, Transgenic; Motor Activity; Neuropsychological Tests; Random Allocation; Reaction Time; Time Factors | 2006 |
Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia.
Topics: Animals; Avoidance Learning; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Hypoxia, Brain; Indans; Male; Memory; Memory Disorders; Piperidines; Rats; Rats, Wistar; Sodium Nitrite; Time Factors | 2006 |
Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Galantamine; Interpersonal Relations; Male; Mice; Mice, Inbred ICR; Microdialysis; Nootropic Agents; Phencyclidine; Prefrontal Cortex; Risperidone; Schizophrenia | 2007 |
Post-ischemic continuous administration of galantamine attenuates cognitive deficits and hippocampal neurons loss after transient global ischemia in gerbils.
Topics: Animals; Avoidance Learning; Behavior, Animal; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Galantamine; Gerbillinae; Hippocampus; Memory; Mice; Motor Activity; Neurons; Nootropic Agents | 2007 |
Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cholinesterase Inhibitors; Cytidine Diphosphate Choline; Disease Models, Animal; Dizocilpine Maleate; Drug Interactions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Male; Mice; Nootropic Agents; Schizophrenia | 2008 |
A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blinking; Cerebellum; Cholinesterase Inhibitors; Cognition Disorders; Conditioning, Classical; Disease Models, Animal; Galantamine; Hippocampus; Male; Neurons; Neuropsychological Tests; Rabbits; tau Proteins | 2007 |
Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Animals; Association Learning; Cholinesterase Inhibitors; Conditioning, Classical; Conditioning, Eyelid; Disease Models, Animal; Female; Galantamine; Humans; Mental Recall; Nootropic Agents; Rabbits; Receptors, Nicotinic | 2000 |
[Influence of an anticholinesterase substance, Nivalin, on the development of experimental arteriosclerosis].
Topics: Animals; Arteriosclerosis; Cholesterol, Dietary; Cholinesterase Inhibitors; Diet, Atherogenic; Disease Models, Animal; Galantamine; Models, Biological; Rabbits | 1971 |